Survodutide

Survodutide directly acts on the liver by simultaneously activating the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), thereby increasing energy consumption and reducing food intake. This dual agonist mechanism gives it unique advantages in weight loss and metabolic improvement, especially in terms of significant improvements in liver fat, inflammation, and fibrosis.